Urolithiasis is referred to as kidney stone and is a condition that is characterized by presence of a calculi or a solid piece material in the urinary tract of an individual. These solid mass commonly known as kidney stone is typically formed in the renal area that is eliminated from the body through the urine stream. The stones that are smaller in size may pass off the body without any symptoms, however, lumps larger than 5 millimeters in size can lead to blockage of the ureter that may cause severe pain in the abdominal area and lower back. This may result in symptoms that includes pain during urination, vomiting or blood in the urine. Urolithiasis is caused due to combination of environmental and genetic factors. It can also be caused due various factors such as obesity, hyperparathyroidism, and high urine calcium levels.
Various kidney stones are asymptomatic in nature and can be discovered during investigations for other medical conditions. Kidney stone is usually diagnosed on the basis of its symptoms through medical imaging, blood testing or urine testing. Kidney stones are usually classified on the basis of the location of their incidence that may be in the kidney (nephrolithiasis, in ureter referred to as ureterolithiasis or in the bladder that is known as cystolithiasis). Lithotripsy is an advised treatment for the management of urolithiasis wherein, the stones can be eliminated by breaking them down into smaller stones through ultrasound that can be able to pass out through the urine.
Rising incidence of chronic kidney diseases is one of the major factors responsible for growth of global urolithiasis management devices market. According to the National Kidney Foundation 2016, around 10% of the global population is affected by chronic kidney diseases, and over 2 million people worldwide are receiving treatment for this disease. According to the World Health Organization 2014, one in every 20 people develop kidney stone at some point in their lives. Moreover, growth of the urolithiasis management devices market can also be attributed to rising adoption of percutaneous nephrolithotomy (PCNL). PCNL refers to the procedures or treatments performed on patients suffering with large or irregularly shaped kidney stones for which normal breaking through shock wave lithotripsy is not enough. According to the American Urological Association 2016, PCNL was reported to be the most fast growing renal disease management technique in the recent past whereas, the European Association of Urology guidelines in 2014 recommended PCNL treatment for renal stones that are larger than 2 cm in their diameter. The National Kidney Foundation 2015, also stated that around half a million patients are admitted in emergency rooms for treatment of kidney stone each year. However, damage of caused to the soft muscles and tissues due to the treatment procedures are expected to hinder the urolithiasis management devices market growth.
On the basis of region, the global urolithiasis management devices market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the global urolithiasis management devices market and is expected to retain its dominance over the forecast period, owing to presence of a large patient pool suffering from urolithiasis. According to the University of Wisconsin Foundation 2013, the incidence of urolithiasis is estimated to be 13% in men and 7% in females in the U.S. Moreover, high presence of leading market players developing innovative and technologically advanced products for the treatment of the kidney disorders in the region is also expected to fuel growth of the regional market. For instance, in 2017 Dornier MedTech, an Atlanta-based medical device company, introduced DORNIER DELTA III, an advanced kidney stone treatment lithotripter that facilitates enhanced efficiency, maximized energy and powerful imaging with its patent protected 'Unified Hand Control' for ease of use and time-saving workflow.
Furthermore, Asia Pacific is expected to witness a maximum traction in the market, which is attributed to a wide number of patients suffering from urolithiasis as well as rising awareness through conduction of campaigns and workshops to educate people regarding the treatments available for management of urolithiasis. For instance, the RG Stone Urology and Laparoscopy Hospital, Mumbai conducted a ‘Free Check-Up for Kidney Stone Camp' in 2012 for people suffering with urological diseases to get free consultation and investigational check-ups.
Key players operating in the global urolithiasis management devices market include C.R. Bard, Cook Medical, Boston Scientific Corporation, Karl Storz, Allengers Medical Systems, Inc., Olympus Corporation, Electro Medical Systems SA, Dornier MedTech GmbH, Direx Group, and others. Market players are focused towards developing technologically advanced products to sustain their presence in the market. For instance, in January 2016, Boston Scientific Corporation introduced the LithoVue single use digital flexible ureteroscope for minimally invasive endoscopic procedures to diagnose kidney stones in the bladder, kidney, and ureter.
On the basis of device type, the global urolithiasis management devices market is segmented into:
- Shock Wave Lithotripters
- Intracorporeal Lithotripters
- Ultrasound Lithotripters
- Pneumatic Lithotripters
- Laser Lithotripters
- Extracorporeal Lithotripters
- Rigid Ureteroscopes
- Semi Rigid Ureteroscopes
- Flexible Ureteroscopes
On the basis of end user, the global urolithiasis management devices market is segmented into:
- Ambulatory Surgical Centers
On the basis of region, the global urolithiasis management devices market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East